Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
Ranibizumab recall: Genentech recalls ocular implant in the US
October 18th 2022The company noted that testing of a commercial supply of the implants, which included exposing them to multiple punctures with a needle, found they did not meet their standards. The company has notified the FDA, and is working with the agency on the recall process.
Read More
Retinal nerve fiber layer thinning associated with the degree of smoking in patients with POAG
October 17th 2022Investigators conducted a longitudinal study of the relationship between smoking and smoking intensity and the rate with which the retinal nerve fiber layer becomes thinner in patients with primary open-angle glaucoma.
Read More
No significant association found between anti-VEGF therapy for ROP and pulmonary hypertension
October 15th 2022Anti-VEGF therapy for ROP has potential ocular and systemic advantages compared with laser but also noted that the systemic risks of anti-VEGF therapy in these infants need to be quantified.
Read More
Risk of rhegmatogenous retinal detachment rises following cataract surgery
October 4th 2022The investigators undertook a study to determine the incidence of rhegmatogenous retinal detachments 1 year after cataract using the IRIS Registry data and to determine the demographic features, ocular comorbidities, and intraoperative factors associated with an increased risk of detachment development.
Read More
Faricimab eradicates center-involved DME faster than aflibercept
October 2nd 2022The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
Read More
Continuous range-of-motion IOL scores high in patient satisfaction
September 30th 2022Investigators reported that the safety and efficacy of the Tecnis Synergy IOL model ZFR00V indicates that it may be a good option for patients who desire meaningful gains in uncorrected visual acuity at all distances.
Read More
Study finds ranibizumab biosimilar equivalent in safety, efficacy for the treatment of wet AMD
September 25th 2022The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the ranibizumab and biosimilar treatment groups.
Read More
Zika virus linked with fundus lesions in newborns in French territories
September 24th 2022This research team conducted a cross-sectional multicenter study to report the ocular fundus manifestations in infants with congenital ZIKV exposure in French Guiana, Martinique, and Guadeloupe, French West Indies.
Read More
Increased dosing for treatment of X-linked retinoschisis linked with inflammation in AAV-RS1 trials
September 20th 2022Investigators have reported good progress in determining how the disease works in the eye; however, a downside is the inflammation that seems to accompany treatment with increased dosing.
Read More
Suspension of AMD treatment during the COVID-19 pandemic resulted in increased rates of vision loss
September 19th 2022Researchers found that the rate of visual decline increased significantly in patients with age-related macular degeneration during the COVID-19 lockdown who were followed over time.
Read More
LIGHT study: First analysis of gene therapy for RPE65 inherited retinal dystrophies
September 3rd 2022At the 1-month evaluation, the full-field stimulus threshold had median decrease of -33.2 decibels (dB) (-33.7; -19.8) dB, which remained stable until the last assessment. Visual fields and visual acuity did not change significantly.
Read More
The Phase 2 Altitude study is an open-label, randomized, controlled, dose-escalation evaluation of RGX-314, evaluating the efficacy, safety, and tolerability of suprachoroidal delivery of RGX-314 in patients with moderately severe/severe non-proliferative diabetic retinopathy or mild proliferative diabetic retinopathy.
Read More